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Abstract
Background: Post kala-azar dermal leishmaniasis (PKDL), a dermal sequel of visceral leishmaniasis, caused by Leishmania
donovani, constitutes an important reservoir for the parasite. Parallel functioning of counter acting immune responses (Th1/
Th2) reflects a complex immunological scenario, suggesting the involvement of additional regulatory molecules in the
disease pathogenesis.
Methodology/Principal Findings: In the present study, human cytokine/chemokine/receptor specific cDNA array technique
was employed to identify modulations in gene expression of host immuno-determinants during PKDL, followed by
evaluation of Th17 type responses by analyzing mRNA and protein expression of Th17 markers (IL-23, IL-17, RORct) and
performing functional assays using Leishmania antigen (TSLA) or recombinant (rec)IL-17. Array analysis identified key
immuno-regulatory molecules including cytokines (TNF-a, IFN-c, IL-10, IL-17), chemokines (MCP-1, MIP-1a), apoptotic
molecules (FasL, TRAIL, IRF-1) and receptors (CD40, Fas). Up regulation in lesional expression of Th17 markers was observed
during PKDL compared to control (IL-17 and IL-23, P=0.0008; RORct, P=0.02). In follow-up samples, chemotherapy
significantly down regulated expression of all markers. In addition, lesional expression of IL-17 was confirmed at protein
level by Immuno-histochemistry. Further, systemic presence of Th17 responses (IL-17 and IL-23) was observed in plasma
samples from PKDL patients. In functional assays, TSLA stimulated the secretion of IL-17 and IL-23 from PBMCs of PKDL
patients, while recIL-17 enhanced the production of TNF-a as well as nitric oxide (NO) in PKDL compared to control (TNF-a,
P=0.0002; NO, P=0.0013). Further, a positive correlation was evident between lesional mRNA expression of IL-17 and TNF-a
during PKDL.
Conclusion/Significance: The results highlight key immune modulators in PKDL and provide evidence for the involvement
of Th17 type responses in the disease pathogenesis.
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Introduction
Visceral leishmaniasis (VL) or kala azar (KA), a potentially fatal
protozoan disease caused by the members of Leishmania donovani
complex, is endemic in 62 countries; with 200 million people at
risk and an estimated 500,000 new cases worldwide annually [1,2].
A small percentage of apparently cured VL patients and
occasionally, persons from endemic areas without a history of
VL, develop a dermal manifestation known as post kala-azar
dermal leishmaniasis (PKDL), characterized by macular, papular
and/or nodular rash. The disease is relatively common in the
Indian subcontinent (India, Nepal, and Bangladesh) and East
Africa where the causative agent is L. donovani. However, the
incidence of PKDL varies from 5–15% in India and to 50–60% in
Sudan, the reasons for which are presently unknown [3]. PKDL
assumes importance being the anthroponotic reservoir of VL in
the Indian subcontinent, and contributing to increasing drug
resistance [4,5].
While it is generally accepted that infection with different
species of Leishmania leads to the establishment of different clinical
forms, the same species of this parasite also leads to different
disease manifestation in VL and PKDL demonstrating that the
host’s immune responses plays a vital role in the disease
pathogenesis. Various factors implicated in the development of
PKDL include nutrition, genetics, inadequate treatment of VL
and immune suppression or reinfection [3]. Studies have suggested
PKDL as a drug dependent manifestation since it is reported more
frequently in SAG treated VL patients [6,7]. However, cases of
PKDL develop even after treatment with other antileishmanial
drugs [8].
A major role of immune responses in the development of PKDL
is well recognized [9,10]. Antecedently, simultaneous presence of
both Th1/Th2 responses with increased ratio of TNF-a/IL-10
and involvement of matrix metalloproteinases (MMPs) and tissue
inhibitors of MMPs (TIMPs) was documented in tissue lesions of
PKDL patients [11,12]. Further, recent reports documented the
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in parasite persistence by establishing positive correlation with
parasite load in PKDL tissue lesions [13,14].
Th17 cells represent a newly described T-cell subset, character-
ized by production of IL-17 [15] and require IL-23 for differen-
tiation and maintenance [16]. Th17 cells play a pivotal role in
autoimmunity and chronic inflammatory diseases [17] and partic-
ipate in defense mechanisms against certain pathogens including L.
donovani [18,19]. Further, IL-17 was associated with intensity of
infiltration and pathogenesis of cutaneous leishmaniasis (CL) [20].
In PKDL, majority of the studies in the past have typically
focused on a small subset of genes as suspected immuno-
determinants for understanding the immune regulation. In this
study, cDNA array technology was employed to obtain a
comprehensive picture of immunological scenario inside lesion
tissue during active disease. Further, the elevated expression of IL-
17 in gene array and clues from studies on CL incited us to
investigate Th17 type responses and their role in PKDL. Here, we
show that IL-17 production was enhanced during PKDL and
contributed to elevated levels of TNF-a and nitric oxide (NO).
Materials and Methods
Patients
PKDL patients originating from Bihar, reporting to the
Department of Dermatology, Safdarjung Hospital, New Delhi
were included in this study (Table 1). Slit-skin smears stained with
Giemsa and histopathology of lesion biopsy for detection of LD
bodies was performed for diagnosis of PKDL. In addition, QPCR
was used to demonstrate Leishmania infection in lesions [21]. HIV
positive patients were excluded from this study. Patients were
treated with oral Miltefosine (150 mg/day) for 2 months which
gave apparent clinical cure in all patients. The healthy individuals,
all male, included in the study were from non-endemic area with
age range of 18–33 years.
Sample collection
Skin biopsies (using 4 mm biopsy punch) from tissue lesions of
PKDL patients were collected for RNA isolation in RNA later
(Ambion, Austin, TX) and in neutralized formalin for IHC.
Biopsies were collected from face or shoulder region. Follow-up
samples were collected from the same site as at pre treatment
stage, one month after completion of treatment. Heparinized
blood was collected for plasma and PBMCs isolation. Normal skin
tissues (n=6, from the shoulder region) and blood (n=10) were
collected from healthy individuals.
Ethics statement
The study was approved by and carried out under the guidelines
of the Ethical Committee of the Safdarjung Hospital, New Delhi,
India. All patients and healthy individuals provided written
informed consent for the collection of samples and subsequent
analysis.
Analysis of mRNA expression using cDNA arrays
Total RNA was isolated from punch biopsy samples collected
from PKDL (n=6) patients and healthy individuals (n=6) using
Trizol (Invitrogen, Green island, NY) method. RNA samples were
pooled in equal amount from each individual. Six micrograms of
DNA-free RNA from each group was reverse transcribed, in the
presence of 50 mCi of a-
33P dATP (specific activity $2000 Ci/
mmol; (Perkin Elmer, San Jose, CA) and gene specific primers for
each gene represented on the array. The cDNA microarray
(AtlasTM; CLONTECH, Palo Alto, CA) consisted of nylon
membranes, spotted with 268 different human genes including
those encoding cytokines, chemokines, growth factors, and cellular
receptors (http://www.clontech.com/support/tools.asp). Briefly,
[
33P] dATP-labelled cDNA was column purified and hybridized,
at high stringency, to cDNA array overnight at 68uC. Membranes
were washed at high stringency and exposed overnight to
phosphor screens. Image was captured with phosphorImager
Typhoon 9210 and analyzed by Imagequant TL software
(Amersham Biosciences, Pittsburgh, PA). The intensity of each
spot was corrected for background levels and normalized using the
housekeeping genes. Array data was analyzed by summing the
duplicated intensity signals for each gene in individual experiments
and taking the average of 3 technical replicates. The data was
expressed as the ratio of mRNA levels in PKDL and controls.
Quantitative mRNA analysis
Real-time PCR was performed as described earlier [14], using
cDNA specific FAM-MGB–labeled Taqman primer sets (Applied
Biosystems, Foster City, CA) for IFN-c (Hs00174143_m1), TNF-a
(Hs00174128_m1), IL-10 (Hs00174086_m1), IL-6 (Hs00174131_
m1), IL-17(Hs00174086_m1), IL-23 (Hs00166229_m1), IL-12b
Table 1. Major characteristics of the study population.
Patients Characteristics PKDL (n=25)
Age (years) range, (mean±SD) 17–39, (25.2466.01)
Sex (M/F) 19/6
Cases reporting history of KA 21
History of KA, range in years,
(mean±SD)
2–27, (8.9066.24)
Type of PKDL lesions
Nodular 11
Macular/Papular 11
Polymorphic 3
Abbreviations: M=Male, F=Female, PKDL=Post kala-azar dermal leishmaniasis,
KA=Kala azar.
doi:10.1371/journal.pntd.0001703.t001
Author Summary
Post kala azar dermal leishamniasis (PKDL), an unusual
dermatosis, develops in 5–15% of apparently cured visceral
leishmaniasis cases in India and in about 60% of cases in
Sudan. PKDL cases assume importance since they consti-
tute an important human reservoir for the parasite. Host
immunological responses, considered as major factors in
PKDL development, are poorly understood. Limited studies
have been performed to explore the host immune
responses and that too, restricted to a few immune
parameters. The present study employed cDNA array
technique that identified various host immuno-determi-
nants including cytokines, chemokines, apoptotic and
signaling molecules which were not reported previously
in PKDL. In addition, we showed for the first time that Th17
responses are present during L. donovani infection in PKDL
which possibly contributes significantly to disease patho-
genesis by inducing TNF-a and nitric oxide production.
Our findings lead to improved understanding of the host
parasite interaction in terms of immune responses and
pathology in tissue lesions of PKDL.
Th17 Responses in PKDL
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34140_m1), IRF-1(Hs00971965_m1) and CD40 (Hs00386
848_m1). VIC-MGB labeled 18S rRNA (4319413E) was used as
endogenous control. The relative quantification of products was
determined by the number of cycles over endogenous control
required to detect the expression of gene of interest.
Cytokine measurement using ELISA
Cytokine levels of IL-17, IL-23 and TNF-a in plasma and
supernatants were determined by ELISA (e-Biosciences, San
Diego, CA) in accordance with manufacturer’s instructions. The
values were calculated as the concentrations in the stimulated
cultures minus the unstimulated controls.
Immunohistochemistry
Skin punch biopsy was collected in neutralized formalin. The
tissue was paraffin embedded and 5 mm sections were prepared on
polylysine coated glass slides from all skin specimens. Immuno-
histochemical staining using anti-human IL-17 (Santa-Cruz, San
Diego, CA) was performed as described earlier [14]. The
immunohistochemical staining for IL-17 was evaluated semi
quantitatively by counting the percentage distribution of lympho-
cytes in the dermal infiltrate showing cytoplasmic staining by
counting at 4006magnification. It was scored as 0: no staining or
less ,10% cells labeled; 1: 11–25% of the cells labeled; 2: 25–50%
of the cells labeled; 3: .50% cells positively labeled. Only
cytoplasmic staining was considered positive.
PBMCs isolation, stimulation and cytokine production
PBMCs were isolated from PKDL patients at pre-treatment,
post-treatment stage and healthy individuals by density gradient
centrifugation with Ficoll-Hypaque (Sigma-Aldrich, St Louis,
MO). The cells were cultured in RPMI 1640 (Sigma-Aldrich),
10% FCS (Life Technologies, NY), glutamine, HEPES and
antibiotics. Briefly, 5610
5 cells were plated in 96 well flat bottom
tissue culture plates (Axygen, Union city, CA, USA) and were kept
only with media (unstimulated) or stimulated with 10 mg/mL of
Phytohemagglutinin (PHA) (Sigma-Aldrich) as a positive control or
with total soluble Leishmania antigen (TSLA) (10 mg/mL) or rec IL-
17 (50 ng/ml) (Peprotech, Rocky Hill, NJ). After 72 hrs of
incubation at 37uC and 5% CO2, supernatants were collected
and stored at 270uC until further analysis.
Estimation of NO production
Nitrite accumulation, an indicator of NO production, was
measured in cell culture supernatants using Griess reagent [22].
Briefly, 50 ml samples of culture supernatants were mixed with an
equal volume of Griess reagent (Sigma-Aldrich) and incubated at
room temperature for 15 min. The absorbance at 570 nm was
measured in a microplate reader. The quantity of the respective
nitrite was calculated in ng/ml using NaNO2 standard curve.
Statistical analysis
Statistical analysis was performed with Mann-Whitney test/
paired t-test using Graph Pad Prism 5 (GraphPad Software, Inc.,
San Diego, CA). Correlation was evaluated using Spearman’s rank
correlation test. P values#0.05 were considered significant.
Results
Study subjects
Of the 25 PKDL patients, Leishman-Donovan (LD) bodies were
seen in 14 patients and histopathological features were compatible
with PKDL in all patients revealing cellular infiltrate consisting of
lymphocytes, plasma cells, and macrophages. All samples were
positive in Leishmania specific quantitative real time PCR (QPCR).
In post-treatment cases, subsidence of indurated lesions leaving
normal or wrinkled skin, and histopathological absence of disease
activity was considered as cured. Further no parasites were
detectable by QPCR in any of post-treatment cases.
Gene expression profile in PKDL
Gene expression analysis using pooled RNA from dermal
lesion tissues of PKDL and normal dermal controls was carried
out using cDNA arrays. Sixty two genes out of 268 arrayed genes
(23.1%) including cytokines, chemokines, receptors and other
regulatory molecules, showed modulation 2 fold or more in tissue
lesions compared to control. Table 2 identifies selected
important genes showing altered expression during PKDL.
Genes that were implicated in Leishmania pathology (VL, CL,
PKDL and MCL), and those related to Th17 type responses
were included in the table. Further, the results of gene array
were validated in individual PKDL samples by QPCR for
selected genes including IFN-c,T N F - a, IL-10, IL-6, IL-12 b,I L -
17, MCP-1, IRF-1 and CD40, all of which showed significantly
higher expression in comparison with controls. Out of 7 control
samples, mRNA level of IFN-c and IRF-1was not detectable in
two, while IL-10 and IL-12b level was not detectable in one
sample (Figure 1).
Transcripts of Th17 markers were elevated in tissue
lesions during PKDL
On the basis of up regulated expression of IL-17 indicated in
array and QPCR analysis, we further investigated gene expression
of Th17 markers in PKDL at pre and post-treatment stages.
Because IL-17 synthesis requires transcription of RORct [23], and
IL-23 enhances expression of RORct [24], we assessed the mRNA
expression of IL-17, ROR-ct and IL-23 in tissue lesions of PKDL
pre-treatment (n=19), post-treatment stage (n=12) and healthy
individuals (n=5) using QPCR. Level of Th17 markers was
significantly elevated in PKDL compared to post-treatment (IL-17,
P=0.0003: IL-23, P,0.0001; RORct, P=0.02) or control (IL-17
and IL-23, P=0.0008; RORct, P=0.02) (Figure 2a). In follow-up
cases (n=12), chemotherapy significantly curtailed the expression
levels (IL-17, P=0.0005; IL-23, P,0.0001 & RORct, P=0.0076)
(Figure 2b).
IL-17
+ cells were evident in tissue lesions of PKDL
patients
Immunohistochemistry (IHC) was utilized to authenticate
translation of IL-17 mRNA into protein in PKDL tissue lesions
(n=8), which showed abundance of IL-17
+ cells within the dense
cellular infiltrate in PKDL compared to control (n=3). Out of 8
PKDL patients, 5 showed IL17
+score of 2, 2 showed score of 1,
and 1 showed 0 score. After treatment, there was a substantial
reduction in IL-17
+ cells and cell infiltrates with all post-treatment
patients showingIL-17 positivity score of 0. In control samples, no
IL-17 staining was observed. Representative examples are
illustrated in Figure 3.
Circulatory levels of IL-17 and IL-23 were elevated during
PKDL and decreased upon treatment
Circulatory Th17 type responses in PKDL were investigated in
plasma samples isolated from blood of PKDL patients at pre-
treatment (n=25), post-treatment stage (n=12) and healthy
individuals (n=10) using cytokine ELISA. Levels (pg/ml) of
Th17 Responses in PKDL
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stage (IL-17: 16.1460.75, IL-23: 45.4863.31) compared to post-
treatment (IL-17: 3.7560.59, P,0.0001; IL-23: 24.9562.43,
P,0.0001) or control (IL-17: 3.82860.54, P,0.0001; IL-23:
14.8661.17, P,0.0001) (Figure 4a). In comparison to pre-
treatment levels, a significant down-regulation was observed for
IL-17 (16.4360.99 vs 3.9360.63; P,0.0001) and IL-23
(54.8664.96 vs 25.9063.43; P=0.0011) in paired samples
(n=12) (Figure 4b).
PBMCs of PKDL patients secreted IL-17 and IL-23 in
response to Leishmania antigen
To investigate antigen specific production of Th17 cytokines,
PBMCs from PKDL (n=8) and healthy individuals (n=6) were
cultured and stimulated with TSLA and IL-17 and IL-23 were
measured in supernatants of stimulated and unstimulated cells
after three days of incubation. Both cytokines (pg/ml) were
significantly produced in PKDL (IL-17: 251.1647.46, IL-23:
331.9632.78) compared to control (IL-17: 28.9361.652,
Table 2. Genes showing altered expression in tissue lesions of PKDL (P) compared to human normal skin (HC).
Gene Name Gene Accession Number Major Functions
Relative mRNA expression
(P/HC)
Cytokine & Chemokine
Tumor necrosis factor-a (TNF-a) X01394 Proinflammatory cytokine, cell proliferation,
differentiation, apoptosis and coagulation
9.0
C-chemokine ligand (CCL)-2 (MCP-1) M24545 Chemokine activity, immunoregulatory and
inflammatory processes
7.3
IL(interlukin)-1b K02770 Mediator of the inflammatory response, cell
proliferation, differentiation, and apoptosis
5.1
IL-17 U32659 Proinflammatory cytokine, high levels are associated
with several chronic inflammatory diseases
5.0
CCL3 (MIP-1a) M23452 Inflammatory responses 4.8
IL-10 M57627 Pleiotropic effects in immunoregulation and inflammation 3.8
IL-12b M65290 Acts on T and natural killer cells, mediate long-term
protection to an intracellular pathogen
3.0
Transforming growth factor (TGF)-b J03241 Embryogenesis and cell differentiation 2.9
CXCL2 X53799 Chemokine with inflammatory activity 2.9
IL-6 X04602 Functions in inflammation and the maturation of B cells 2.7
IL-4 M13982 Pleiotropic cytokine, regulator of NO synthesis 2.6
IL-8 Y00787 Chemoattractant and inflammatory response 2.5
Interferon (IFN)-c X01992 Immunoregulatory and anti-tumor properties,
activator of macrophages
2.4
IK cytokine X01992 Down regulator of HLA class II 2.2
IL-2 A14844 Proliferation of T and B lymphocytes 2.2
CCL5 M21121 Chemoattractant for monocytes, T cells and eosinophils 0.47
Receptors
IL-2receptor-c D11086 Signaling initiation and T cell proliferation 6.0
TRAILR2 AF016268 Apoptosis mediation 3.9
CD40 X60592 T cell-dependent immunoglobulin class switching,
memory B cell development
3.7
C-chemokine receptor-1 D10925 Receptor for CCL3, chemokine mediated signaling 3.4
IL-4 receptor X52425 Receptor for IL-4, promote differentiation of Th2 cells 2.8
Fas Z70519 physiological regulation of programmed cell death 2.2
IL-1receptor type II X59770 Acts as a decoy receptor for its ligands 0.45
Others
IFN regulatory factor-1 (IRF-1) X14454 Acts as an activator of interferon-a and b transcription 8.0
FASL D38122 Ligand for Fas, triggering of apoptosis 4.1
Epstine bar virus-3 (EBI-3) L08187 IL-27 formation for activation of JAK/STAT pathway 3.4
CD40 ligand L07414 Ligand for CD40, regulates B cell function 3.3
Protein tyrosine kinase-7 U33635 Tyrosine kinase, cell adhesion molecule 2.6
TRAIL U57059 Induces apoptosis in transformed and tumor cells 2.2
Programmed cell death 1 AF022385 Apoptosis, modulate ERK pathway 2.0
Calgranulin B X06233 Cell cycle progression and differentiation 0.4
doi:10.1371/journal.pntd.0001703.t002
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levels in post-treatment samples were comparable to pre treatment
stage (IL-17: 191.6633.43, P=0.35; IL-23: 304.1621.72,
P=0.52) and significantly elevated compared to control (IL-17,
P=0.002; IL-23, P,0.0001) (Figure 5a).
IL-17 stimulation enhanced production of TNF-a and NO
by PBMCs from PKDL patients
IL-17 is established as a strong inducer of TNF-a production by
monocytes [25]. In order to find out the possible association of IL-
17 and TNF-a in PKDL, levels of TNF-a (pg/ml) were measured
in supernatants from PBMCs of PKDL (n=8) and healthy
individuals (n=6) stimulated with TSLA or recombinant (rec)IL-
17. Both TSLA and recIL-17 stimulated production of TNF-a
(815.4666.01, 530.5673.68) which was significantly elevated in
PKDL compared to control (81.8465.32, 65.3865.08, P=0.0007
and 0.0002) (Figure 5b). In response to TSLA, a significant
increase was observed in the level of TNF-a in post-treatment
samples compared to control (P=0.002, while the levels were
comparable between pre and post-treatment stage (699.5645.39,
P=0.28). In response to recIL-17, a significant decrement was
observed in the level of TNF-a in post-treatment samples
compared to pre-treatment samples (70.16612.21, P=0.0007).
The levels were comparable between post-treatment samples and
controls (P=0.81) (Figure 5b). Since IL-17 is an inducer of NO
production in various cell types [26], we also assessed the influence
of IL-17 on NO production. In PKDL, both TSLA and IL-17
stimulated production of NO (585.7693.74, 398.9671.21) which
was significantly elevated compared to post-treatment samples
(232.1618.42, P=0.007; 139.1611.41, P=0.009) or control
(76.6863.23, P=0.0007; 53.2663.69, P=0.0013) (Figure 5c).
The level of NO was significantly higher in post-treatment samples
than controls in response to both TSLA and recIL-17 (P=0.002)
(Figure 5c).
Figure 1. Validation of cDNA array results using real time PCR in tissue lesions of PKDL patients. Relative mRNA levels of IFN-c, TNF-a, IL-
6, IL-10, IL-12b, IL-17, MCP-1, CD40 and IRF-1 was determined by QPCR in tissues lesions of PKDL patients (n=10) or control tissues (n=7). The relative
quantification of products was determined by the number of cycles over endogenous control (18sRNA) required to detect the gene expression of
interest. **P,0.01, and ***P,0.001.
doi:10.1371/journal.pntd.0001703.g001
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www.plosntds.org 5 June 2012 | Volume 6 | Issue 6 | e1703Figure 2. mRNA expression of Th17 markers in PKDL. Relative mRNA levels of IL-17, IL-23 and RORct was determined by QPCR in (a) tissues
lesions at pretreatment (n=19), post treatment (n=12), or control tissues (n=5) or (b) in paired samples (n=12). The Y axis represents the number of
cycles over endogenous control (18sRNA) required to detect the gene expression of interest. *P,0.05, **P,0.01, and ***P,0.001.
doi:10.1371/journal.pntd.0001703.g002
Figure 3. Immuno-histochemical staining of IL-17. A light microscopic analysis of IL-17 immuno-staining in dermal tissue lesion sections of
PKDL at pre-treatment, post-treatment stages and normal skin of healthy individuals. Intense IL-17 staining was observed within the inflammatory
infiltrate at pre-treatment stage in PKDL. Magnification 106(inset 406).
doi:10.1371/journal.pntd.0001703.g003
Th17 Responses in PKDL
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We measured mRNA expression of TNF-a in PKDL tissue
lesions and investigated for any association between TNF-a and
IL-17 expressions in the same set of patients. The message levels of
TNF-a were found significantly elevated at pre-treatment stage
compared to control (P=0.0008) and decreased with chemother-
apy at post-treatment stage (P,0.0001). Further analysis estab-
lished a positive correlation between mRNA expression of IL-17
and TNF-a in tissue lesions of PKDL patients (r=0.77) (Figure 6).
Such correlation was not observed for IL-23 or RORct.
Discussion
During the interaction with host cell, parasites attempt to take
over cellular functions to their advantage while the host cell
counteracts by mounting a variety of defensive responses that
include induction of various cytokines, chemokines or other
regulatory molecules, all of which are accompanied by changes in
gene expression. In the present study, we document the
modulation in gene expression profile of various cytokines,
chemokines, receptors and apoptotic molecules during L. donovani
infection in PKDL. The expression of cytokines IFN-c, TNF-a,
IL-10 and TGF-b were found elevated, similar to previous reports
[11], with TNF-a showing the highest expression (9 fold) in
cytokine category. Further, chemokines including IL-8, CXCL-2,
MIP-1a, MIP-1b and MCP-1, were found up regulated, all of
which are known to primarily activate the microbicidal activity, by
promoting chemotaxis of neutrophils and other target cells.
Similarly, in Leishmania infection, MCP-1 and MIP-1a have been
associated with lesional macrophage infiltration, enhancement of
nitric oxide production and stimulation of leishmanicidal activity
[27]. Higher expression of chemokines in PKDL implies that these
may have a role in shifting the parasite from viscera to dermis, in
keeping with a report demonstrating the presence of chemokine
binding molecules on the surface of the kinetoplastid parasite [28].
Secondly, as MIP-1a and MIP-1b are potent chemo-attractants
for monocyte/macrophages, these may be important in attracting
the uninfected immature macrophages. Such cells would provide a
safe shelter for the parasite as they get infected but do not kill the
parasite, thus contributing towards persistence of parasites.
CD40, a member of the tumor necrosis factor receptor
superfamily, interacts with CD40L on activated T cells and helps
in immune activation during bacterial, fungal, parasitic and viral
infections [29]. In our study, both CD40 and CD40L showed a
moderate increment in gene expression in active PKDL. Studies in
context with Leishmania have demonstrated that the interaction of
CD40 with CD40L activates the macrophages resulting in killing
of amastigotes [30] but at the same time, a weak CD40 signal
promotes IL-10 and reduces IL-12 production [31]. Therefore, it
remains a paradox whether CD40 induces host protection or
disease promotion.
Another interesting molecule modulated in PKDL was inter-
feron regulatory factor (IRF)-1. It was originally discovered as a
protein that binds to DNA sequences termed IRF-Es [32]. It is
required for in vivo generation of Th1 responses through IL-12
production [33]. Infection of human dendritic cells with L. major
activated IRF-1 resulting in IL-12 production [34]. Furthermore,
IRF-1 acted as a mediator of cytokine-induced apoptosis as
hepatocytes from IRF-1-deficient mice were completely resistant
to apoptosis induction by IFN-c [35]. A pronounced expression of
IRF-1 pointed towards its involvement in PKDL pathogenesis;
however its function during L.donovani infection in humans is not
known.
In addition to prevalence of Th1/Th2 responses, elevated
expression of IL-17 (5 fold) in array results pointed towards the
presence of Th17 type responses in PKDL. IL-17 is involved in
regulating tissue inflammation, development of autoimmune
Figure 4. Plasma levels of IL-17 and IL-23 in PKDL. Plasma levels of IL-17 and IL-23 determined by ELISA (a) at pre (n=25), post-treatment stage
(n=15), controls (n=10) or (b) in paired samples (n=12) (b). Individual values (pg/ml) are presented and the mean6SE are shown. **P,0.01, and
***P,0.001.
doi:10.1371/journal.pntd.0001703.g004
Th17 Responses in PKDL
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Currently, there is limited information available related to role of
IL-17 in Leishmania infection. Given the chronic inflammation and
neutrophil/macrophage migration during Leishmania infection
[37], it is logical to speculate that IL-17 may have a pivotal role
in PKDL. At pre-treatment stage, elevated levels of IL-17, along
with a high expression of Th17 associated markers (IL-23 and
RORct) indicated presence of Th17 type responses. Further, at
protein level, immuno-histochemical identification of IL-17
+ cells
in lesional cellular infiltrate and up regulation in both IL-17 and
IL-23 levels in circulation of PKDL patients, confirmed lesional as
well as systemic presence of Th17 responses during disease. Our
results are in conjunction with recent reports on muco-cutaneous
Leishmaniasis (ML) and CL, showing elevated levels of IL-17 and
associated cytokines [20,38]. IL-23, a heterodimeric cytokine, is
associated with the induction of Th17 cells [39]. Products from
microorganisms, including bacteria, intracellular parasites, viruses
and fungi are strong inducers of IL-23 production in macrophages,
monocytes, neutrophils, and DCs [40]. M. tuberculosis infection in
human DCs induced IL-23 production which further contributed
to IL-17 production from CD4
+ cells [41]. In this study, IL-23
expression was found up regulated and PBMCs from PKDL
Figure 5. Levels of cytokine nitric oxide and in PBMCs supernatants stimulated with TSLA or recIL-17. (a) IL-17 and IL-23 levels in PBMCs
of PKDL pre (n=8), post (n=6) and control subjects (n=6) stimulated with total soluble Leishmania antigen (TSLA). (b) Release of TNF-a (pg/ml) or (c)
NO (ng/ml) from PBMCs of same set of subjects following incubation with TSLA (10 mg/ml) or recombinant IL-17 (50 ng/ml) for 72 h at 37uC. Cytokine
levels were determined by ELISA and NO was quantified by Griess reagent method in culture supernatants. The concentrations shown are the values
in the stimulated cultures minus the unstimulated controls. Individual values (pg/ml) are presented and the mean6SE are shown. **P,0.01, and
***P,0.001.
doi:10.1371/journal.pntd.0001703.g005
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antigen. In addition to IL-23, generation of human Th17 cells is
dependent on IL-1b, TGF-b and IL-6 [19] all of which were found
up regulated (5.1, 2.9 and 2.1 fold respectively) in PKDL (Table 2).
Thus, we suggest that abundance of IL-17 in PKDL could be due
to enhanced IL-23 level which, in association with IL-6, TGF-b
and IL-1b, induces differentiation to IL-17 secreting Th17 cells. In
follow-up cases, after stimulation with TSLA, the Th17 cytokines
levels were comparable to pre treatment stage which may be a
memory T cell response. Similar to our results, antigen specific
Th17 cytokine responses have been demonstrated in PBMCs from
CL and ML patients [20]. In contrast to PKDL, a defective Th17
response in VL against whole parasite or soluble antigen is
reported [18]. Possible discrepancy between VL and PKDL could
be context dependent due to different niche and clinical
manifestation.
To our knowledge, this is the first report demonstrating up
regulation of IL-17 during PKDL, which further tended our
interest to investigate the role of this cytokine. IL-17 is a known
inducer of TNF-a production from endothelial cells, epithelial
cells, monocytes and macrophages [25,42]. Increased production
of TNF-a in PBMCs on addition of external IL-17 confirmed the
impact of IL-17 towards enhanced TNF-a level. In contrast to
PKDL, low abundance of IL-17 has been demonstrated recently
in VL [43] that explains the impairment in the production of
TNF-a by monocytes in VL [44]. TNF-a is functionally linked to
the Th17 pathway by its ability to activate myeloid dendritic cells
that synthesize IL-23 and other regulators of T-cell development
[45,46]. Thus, TNF-a may serve as an indirect activator of Th17
responses and a significant positive correlation between these two
molecules, as evident in our study, indicated their interrelation-
ship. In addition, IL-17 stimulates NO production in mammalian
cells [26] and an elevated level of NO has been shown in PKDL
serum samples [47]. Stimulation with IL-17 enhanced the NO
level in culture supernatants in PBMCs, establishing the associ-
ation of IL-17 with elevated NO level. In CL, different studies
have shown presence of Th17 responses, up regulation in iNOS
expression and increase in NO serum levels [20,48,49], however,
association between these molecules has not been reported. Here,
we demonstrated a direct functional association of IL-17 and NO
production during PKDL.
Recently, we have demonstrated accumulation of lesional
Tregs and their correlation with parasite load in PKDL [14].
Here we provide evidence for enhanced Th17 responses in the
same. Thus, we show a paradoxical gene expression signatures
associated with inhibition of the immune response (Tregs) and the
proinflammatory response (IL-17, TNF-a) in PKDL. However,
no correlation was observed between parasite load and cytokine
mRNA levels of Th17 markers. Previously, a number of studies
have identified coexistence of Th17 and Treg cells in various
diseases [50–53]. Considering the association of IL-17 with
resistance to L. donovani infection [18], the data suggests that
during PKDL, parasite induces production of Tregs that
counteract inflammatory responses (IL-17, TNF-a and NO) by
secreting IL-10 and promoting parasite persistence. It has been
shown that adoptive transfer of Tregs inhibits ex vivo inflamma-
tory Th17 responses in humans [54], although during active
tuberculosis Tregs facilitated mycobacterial replication by inhib-
iting Th1 rather than Th17 responses [51]. In case of PKDL,
further investigations are needed to explore cross talk between
these counter acting responses.
Taken together, this study reveals that L. donovani infection has a
remarkable effect on host cellular gene expression, and identified
several new molecules whose implication remains to be defined in
context with critical and non-overlapping functions of immuno-
modulators in regulating immunity in PKDL. Further, this study
demonstrated enhanced expression and antigen specific stimula-
tion of Th17 cytokines and the involvement of IL-17 in PKDL
pathogenesis by demonstrating its association with TNF-a and
NO production. Based on longitudinal follow-up studies on
L.donovani infected humans [18] and present results, we suggest
that enhanced Th17 responses may have a role in parasite
clearance during PKDL. Considering the plasticity between Tregs
and Th17 [55], it would be of great interest to investigate
reciprocal regulation of these cells in PKDL. Improved mecha-
nistic insight into the collaborative interaction between these
immuno-determinants during PKDL would undoubtedly pave
way for filling up gaps in our basic knowledge and contribute in
developing strategies for disease control.
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Figure 6. mRNA expression of TNF-a and its correlation with IL-17. Relative mRNA levels of TNF-a in lesion tissues of PKDL patients
determined by real time PCR (a) at pretreatment (n=19) or post treatment (n=12), or control tissues (n=5) or (b) in paired samples (n=12) and (c)
Correlation between IL-17 and TNF-a expression in tissue lesions of PKDL. (r) represents Spearman’s rank correlation coefficient. **P,0.01, and
***P,0.001.
doi:10.1371/journal.pntd.0001703.g006
Th17 Responses in PKDL
www.plosntds.org 9 June 2012 | Volume 6 | Issue 6 | e1703References
1. Herwaldt BL (1999) Leishmaniasis. Lancet 354: 1191–1199.
2. Desjeux P (2004) Leishmaniasis: current situation and new perspectives. Comp
Immunol Microbiol Infect Dis 27: 305–318.
3. Zijlstra EE, Musa AM, Khalil EAG, EI-Hassan IM, EI-Hassan AM (2003) Post
kala azar dermal leishmaniasis. Lancet Infect Dis 3: 87–98.
4. Singh R, Kumar D, Ramesh V, Negi NS, Singh S, et al. (2006). Visceral
leishmaniasis, or kala azar (KA): high incidence of refractoriness to antimony is
contributed by anthroponotic transmission via post-KA dermal leishmaniasis.
J Infect Dis 194: 302–306.
5. Sundar S, Kumar K, Chakravarty J, Agrawal S, Agrawal A, et al. (2006). Cure
of antimony-unresponsive Indian post-kala-azar dermal leishmaniasis with oral
miltefosine. Trans R Soc Trop Med Hyg 100: 698–700.
6. Saha S, Mondal S, Ravindran R, Bhowmick S, Modak D, et al. (2007) IL-10 and
TGF-beta-mediated susceptibility in Kala-azar and Post-kala-azar dermal
Leishmaniasis: the significance of amphotericin B in the control of Leishmania
donovani infection in India. J Immunol 179: 5592–5603.
7. Thakur CP, Kumar A, Mitra G, Thakur S, Sinha PK, et al. (2008) Impact of
amphotericin-B in the treatment of kala-azar on the incidence of PKDL in
Bihar, India. Indian J Med Res 128: 38–44.
8. Kumar D, Ramesh V, Verma S, Ramam M, Salotra P (2009) Post-kala-azar
dermal leishmaniasis (PKDL) developing after treatment of visceral leishmaniasis
with amphotericin B and miltefosine. Ann Trop Med Parasitol 103: 727–30.
9. Gasim S, Elhassan AM, Khalil EA, Ismail A, Kadaru AM, et al. (1998) High
levels of plasma IL-10 and expression of IL-10 by keratinocytes during visceral
leishmaniasis predict subsequent development of post-kala-azar dermal leish-
maniasis. Clin Exp Immunol 111: 64–69.
10. Ismail A, El Hassan AM, Kemp K, Gasim S, Kadaru AE, et al. (1999)
Immunopathology of post kala-azar dermal leishmaniasis (PKDL): T-cell
phenotypes and cytokine profile. J Pathol 189: 615–622.
11. Ansari NA, Ramesh V, Salotra P (2006) Interferon (IFN)-gamma, tumor
necrosis factor-alpha, interleukin-6, and IFN-gamma receptor 1 are the major
immunological determinants associated with post-kala azar dermal leishmani-
asis. J Infect Dis 194: 958–965.
12. Ansari NA, Katara GK, Ramesh V, Salotra P (2008) Evidence for involvement
of TNFR1 and TIMPs in pathogenesis of post-kala-azar dermal leishmaniasis.
Clin Exp Immunol 154: 391–398.
13. Ganguly S, Mukhopadhyay D, Das NK, Chaduvala M, Sadhu S, et al. (2010)
Enhanced lesional Foxp3 expression and peripheral anergic lymphocytes
indicate a role for regulatory T cells in Indian post-kala-azar dermal
leishmaniasis. J Invest Dermatol 130: 1013–1022.
14. Katara GK, Ansari NA, Verma S, Ramesh V, Salotra P (2011) Foxp3 and IL -
10 expression correlates with parasite burden in lesional tissues of post kala azar
dermal leishmaniasis (PKDL) patients. PLoS Neg Trop Dis 5: e1171
15. Liang SC, Tan XY, Luxenberg DP, Karim R, Dunussi-Joannopoulos K, et al.
(2006) Interleukin (IL)-22 and IL-17 are coexpressed by Th17 cells and
cooperatively enhance expression of antimicrobial peptides. J Exp Med 203:
2271–2279.
16. Volpe E, Servant N, Zollinger R, Bogiatzi SI, Hupe ´ P, et al. (2008) A critical
function for transforming growth factor-beta, interleukin 23 and proinflamma-
tory cytokines in driving and modulating human T(H)-17 responses. Nat
Immunol 9: 650–657.
17. Crome SQ, Wang AY, Levings MK (2010) Translational mini-review series on
Th17 cells: function and regulation of human T helper 17 cells in health and
disease. Clin Exp Immunol 159: 109–119.
18. Pitta MG, Romano A, Cabantous S, Henri S, Hammad A, et al. (2009) IL-17
and IL-22 are associated with protection against human kala azar caused by
Leishmania donovani. J Clin Invest 119: 2379–2387.
19. Khader SA, Gopal R (2010) IL-17 in protective immunity to intracellular
pathogens. Virulence 1: 423–427.
20. Bacellar O, Faria D, Nascimento M, Cardoso TM, Gollob KJ, et al. (2009)
Interleukin 17 production among patients with American cutaneous leishman-
iasis. J Infect Dis 200: 75–78.
2 1 .V e r m aS ,K u m a rR ,K a t a r aG K ,S i n g hL C ,N e g iN S ,e ta l .( 2 0 1 0 )
Quantification of parasite load in clinical samples of leishmaniasis patients: IL-
10 level correlates with parasite load in visceral leishmaniasis. PLoS One 5:
e10107
22. Green LC, Wagner DA, Glogowski J, Skipper PL, Wishnok JS, et al. (1982)
Analysis of nitrate, nitrite, and [15N] nitrate in biological fluids. Anal Biochem
126: 131–138.
23. Kostka SL, Dinges S, Griewank K, Iwakura Y, Udey MC, et al. (2009) IL-17
promotes progression of cutaneous leishmaniasis in susceptible mice. J Immunol
182: 3039–3046.
24. Ivanov II, Zhou L, Littman DR (2007) Transcriptional regulation of Th17 cell
differentiation. Semin Immunol 19: 409–417.
25. Jovanovic DV, Di Battista JA, Martel-Pelletier J, Jolicoeur FC, He Y, et al.
(1998) IL-17 stimulates the production and expression of proinflammatory
cytokines, IL-beta and TNF-alpha, by human macrophages. J Immunol 160:
3513–3521.
26. Miljkovic D, Trajkovic V (2004) Inducible nitric oxide synthase activation by
interleukin-17. Cytokine Growth Factor Rev 15: 21–32.
27. Brandonisio O, Panaro MA, Fumarola I, Sisto M, Leogrande D, et al. (2002)
Macrophage chemotactic protein-1 and macrophage inflammatory protein-1
alpha induce nitric oxide release and enhance parasite killing in Leishmania
infantum-infected human macrophages. Clin Exp Med 2: 125–129.
28. Roychoudhury K, Dasgupta B, Sen P, Laskay T, Solbach W, et al. (2006)
Evidence of direct interactions between the CC-chemokines CCL3, CCL4 and
CCL5 and Leishmania promastigotes. Mol Biochem Parasitol 150: 374–377.
29. Grewal IS, Borrow P, Pamer EG, Oldstone MB, Flavell RA (1997) The CD40-
CD154 system in anti-infective host defense. Curr Opin Immunol 9: 491–497.
30. Heinzel FP, Rerko RM, Hujer AM (1998) Underproduction of interleukin-12 in
susceptible mice during progressive leishmaniasis is due to decreased CD40
activity. Cell Immunol 184: 129–142.
31. Mathur RK, Awasthi A, Wadhone P, Ramanamurthy B, Saha B (2004)
Reciprocal CD40 signals through p38MAPK and ERK-1/2 induce counter-
acting immune responses. Nat Med 10: 540–544.
32. Miyamoto M, Fujita T, Kimura Y, Maruyama M, Harada H, et al. (1988)
Regulated expression of a gene encoding a nuclear factor, IRF-1, that
specifically binds to IFN-beta gene regulatory elements. Cell 54: 903–913.
33. Lohoff M, Ferrick D, Mittrucker HW, Duncan GS, Bischof S, et al. (1997)
Interferon regulatory factor-1 is required for a T helper 1 immune response in
vivo. Immunity 6: 681–689.
34. Jayakumar A, Donovan MJ, Tripathi V, Ramalho-Ortigao M, McDowell MA
(2008) Leishmania major infection activates NF-kappaB and interferon regulatory
factors 1 and 8 in human dendritic cells. Infect Immun 76: 2138–2148.
35. Kano A, Haruyama T, Akaike T, Watanabe Y (1999) IRF-1 is an essential
mediator in IFN-gamma-induced cell cycle arrest and apoptosis of primary
cultured hepatocytes. Biochem Biophys Res Commun 257: 672–677.
36. Kolls JK, Linden A (2004) Interleukin-17 family members and inflammation.
Immunity 21: 467–476.
37. Solbach W, Laskay T (2000). The host response to Leishmania infection. Adv
Immunol 74: 275–317.
38. Boaventura VS, Santos CS, Cardoso CR, de Andrade J, Dos Santos WL, et al.
(2010) Human mucosal leishmaniasis: neutrophils infiltrate areas of tissue
damage that express high levels of Th17-related cytokines. Eur J Immunol 40:
2830–2836.
39. Lyakh L, Trinchieri G, Provezza L, Carra G, Gerosa F (2008) Regulation of
interleukin-12/interleukin-23 production and the T-helper 17 response in
humans. Immunol Rev 226: 112–131.
40. Ma X, Trinchieri G (2001) Regulation of interleukin-12 production in antigen-
presenting cells. Adv Immunol 79: 55–92.
41. Gerosa F, Baldani-Guerra B, Lyakh LA, Batoni G, Esin S (2008) Differential
regulation of interleukin 12 and interleukin 23 production in human dendritic
cells. J Exp Med 205: 1447–1461.
42. Korn T, Bettelli E, Oukka M (2009) IL-17 and Th17 Cells. Annu Rev Immunol
27: 485–517.
43. Ansari NA, Kumar R, Gautam S, Nyle ´n S, Singh OP, et al. (2011) IL-27 and IL-
21 are associated with T cell IL-10 responses in human visceral leishmaniasis.
J Immunol 186: 3977–3985.
44. Peruhype-Magalhaes V, Martins-Filho OA, Prata A, Silva Lde A, Rabello A, et
al. (2006) Mixed inflammatory/regulatory cytokine profile marked by simulta-
neous raise of interferon-gamma and interleukin-10 and low frequency of
tumour necrosis factor-alpha(+) monocytes are hallmarks of active human
visceral Leishmaniasis due to Leishmania chagasi infection. Clin Exp Immunol 146:
124–132.
45. Gottlieb AB, Chamian F, Masud S, Cardinale I, Abello MV, et al. (2005) TNF
inhibition rapidly down-regulates multiple proinflammatory pathways in
psoriasis plaques. J Immunol 175: 2721–2729.
46. Zaba LC, Cardinale I, Gilleaudeau P, Sullivan-Whalen M, Sua ´rez-Farin ˜asM,et
al. (2007) Amelioration of epidermal hyperplasia by TNF-a inhibition is
associated with reduced Th17 responses. J Exp Med 204: 3183–3194.
47. Ansari NA, Sharma P, Salotra P (2007) Circulating nitric oxide and C-reactive
protein levels in Indian kala azar patients: correlation with clinical outcome. Clin
Immunol 122: 343–348.
48. Cabrera M, Rodriguez O, Monsalve I, Tovar R, Hagel I (2003) Variations in
the serum levels of soluble CD23, nitric oxide and IgE across the spectrum of
American cutaneous leishmaniasis. Acta Trop 88: 145–151.
49. Kumar R, Bumb RA, Salotra P (2010) Evaluation of localized and systemic
immune responses in cutaneous leishmaniasis caused by Leishmania tropica:
interleukin-8, monocyte chemotactic protein-1 and nitric oxide are major
regulatory factors. Immunology 130:193–201.
50. Martin-Orozco N, Muranski P, Chung Y, Yang XO, Yamazaki T, et al. (2009)
T helper 17 cells promote cytotoxic T cell activation in tumor immunity.
Immunity 31: 787–798.
51. Marin ND, Paris SC, Velez VM, Rojas CA, Rojas M, et al. (2010) Regulatory T
cell frequency and modulation of IFN-gamma and IL-17 in active and latent
tuberculosis. Tuberculosis 90: 252–261.
52. Zhang L, Yang XQ, Cheng J, Hui RS, Gao TW (2010) Increased Th17 cells are
accompanied by FoxP3(+) Treg cell accumulation and correlated with psoriasis
disease severity. Clin Immunol 135:108–117.
Th17 Responses in PKDL
www.plosntds.org 10 June 2012 | Volume 6 | Issue 6 | e170353. Wang Q, Zheng Y, Huang Z, Tian Y, Zhou J, et al. (2011) Activated IL-23/IL-
17 pathway closely correlates with increased Foxp3 expression in livers of
chronic hepatitis B patients. BMC Immunol 12: 25.
54. Crome SQ, Clive B, Wang AY, Kang CY, Chow V, et al. (2010) Inflammatory
effects of ex vivo human Th17 cells are suppressed by regulatory T cells.
J Immunol 185: 3199–3208.
55. Awasthi A, Murugaiyan G, Kuchroo VK (2008) Interplay between effector
Th17 and regulatory T cells. J Clin Immunol 28: 660–670.
Th17 Responses in PKDL
www.plosntds.org 11 June 2012 | Volume 6 | Issue 6 | e1703